August 24, 2026 Building a Stronger Path to Therapies for Hereditary Spastic Paraplegia and Primary Lateral Sclerosis For more than 20 years, the Spastic Paraplegia Foundation (SPF) has worked toward a future with better...
August 20, 2026 C-Path CEO Klaus Romero Talks One to Millions on The BioCentury Show Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies...
July 29, 2026 Scaling the Science: The Maturation of NAMs and the Demand for Validated Scaling The commercial and regulatory reality of New Approach Methodologies (NAMs) materialized rapidly this conference season.
July 20, 2026 Pamela Dasher Lopez Expected Interesting Courses from the University of Arizona Regulatory Science Certificate. She Came Away Understanding Drug Development More Deeply Than She Expected To. "We all know what happened in March 2020," Pamela Dasher Lopez stated. She was in Sydney then...
July 14, 2026 Karen Bernstein, One of Biotech’s Most Influential Voices, Elected C-Path Board Chair TUCSON, Ariz., July 14, 2026 — Critical Path Institute® (C-Path) today announced that its Board of Directors has elected...
July 29, 2026 eCOA Consortium and PCE Consortium Webinar Recording: Event Driven eDiaries At C-Path’s 2026 Clinical Outcome Assessment Program Annual Meeting, attendees heard a brief overview of...
July 9, 2026 Wendy Ruyle Learned That Groundbreaking Science Alone Is Not Enough Early in her career, Wendy Ruyle worked as a study coordinator on clinical trials, a role that put her in direct contact with...
April 1, 2026 Advancing Rare Disease Innovation Through Responsible Data Sharing — Key Takeaways from the RISE Together: Data Sharing Across the Rare Disease Ecosystem At a recent public workshop co-convened by the Duke-Margolis Institute for Health Policy...
March 31, 2026 C-Path Newsletter Q1 2026: Momentum in Motion As we close the first quarter of the year, we are energized by the opportunities ahead to further strengthen collaboration...
March 26, 2026 BioCentury Article: Critical Path Institute Aims to Bring Scale to Individualized Medicines FDA’s plausible mechanism framework aims to accelerate and expand drug development for patients...
